PCA stroke was under-represented in or excluded from the clinical trials examining
thrombolysis based on the PWI-DWI mismatch concept. We present 6 patients with PCA …

We thought your readers would like to know that mild or improving stroke symptoms remain
a common cause for exclusion from intravenous tissue plasminogen activator (tPA) …

Intravenous (IV) recombinant tissue plasminogen activator (rtPA) is the only Food and Drug
Administration (FDA)-approved pharmacological therapy for acute ischemic stroke (AIS)[1 …

The clinical constellation of a large MCA stroke with a substantial mismatch between DWI
and PWI in the 3-to 6-hour time window is for many stroke neurologists an indication for the …

Background Patients presenting with mild stroke symptoms are excluded inconsistently from
intravenous (IV) thrombolysis. We aimed to compare acute magnetic resonance imaging …

Background: Intravenous thrombolysis (IVT) is a standard treatment for both anterior
circulation ischemic stroke (ACIS) and posterior circulation ischemic stroke (PCIS). PCIS is a …

Background. Intravenous thrombolysis with tissue plasminogen activator is an approved and
effective therapy for acute ischemic stroke within the first 3 hours from onset. In addition to …

BACKGROUND AND PURPOSE: IV administration of tPA is accepted as a standard
treatment for acute cerebral ischemia, but the clinical outcomes cannot be guaranteed in …

Background: Standard selection criteria for thrombolysis typically exclude patients with acute
ischemic stroke with unclear onset. Multimodal MRI screening may be able to identify those …

EDITORIAL thrombolysis rate was 11.3% and it was associated with worse outcome. the
worse outcome is unexpected, but can be explained by selective thrombolysis practice in …